Moonlake Immunotherapeutics Form 4 insider transactions

MoonLake Immunotherapeutics director Spike Loy was granted options to purchase 6,682 Class A ordinary shares, with an exercise price of $48.83 per share, as disclosed in a recent SEC Form 4 filing.

MoonLake Immunotherapeutics' Director, Ramnik Xavier, was granted options to purchase 6,682 Class A ordinary shares, aligning his incentives with the company's long-term performance.

MoonLake Immunotherapeutics director Catherine Moukheibir was granted 6,682 stock options with an exercise price of $48.83, vesting by June 2026 or the next annual general meeting.

MoonLake Immunotherapeutics Director Andrew John Phillips was granted options to purchase 6,682 Class A ordinary shares at an exercise price of $48.83, vesting by June 2026.

CEO Jorge Santos da Silva of MoonLake Immunotherapeutics reports acquisition of restricted stock and total holdings.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, was granted stock options to purchase 139,273 Class A ordinary shares.

Matthias Bodenstedt, CFO of MoonLake Immunotherapeutics, reports the acquisition of 95,763 Class A ordinary shares.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, reports the exchange of MoonLake AG shares for Class A ordinary shares and the cancellation of Class C ordinary shares.

BVF Partners L.P. and affiliated entities reported selling a portion of their MoonLake Immunotherapeutics shares at a price of $50.0016 per share, resulting in a decreased beneficial ownership.

Director Simon Sturge of MoonLake Immunotherapeutics sold 171,000 Class A ordinary shares on October 4, 2024, at an average price of $53.72, totaling approximately $9.2 million.

BVF Partners and affiliated entities report changes in beneficial ownership of MoonLake Immunotherapeutics shares, including the acquisition of options and adjustments to direct holdings.

Director Catherine Moukheibir acquired options to purchase 7,688 Class A Ordinary Shares of MoonLake Immunotherapeutics on June 6, 2024.

Director Andrew John Phillips acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.

Director Ramnik Xavier acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.

Director Simon Sturge acquired options to purchase 7,688 Class A ordinary shares of MoonLake Immunotherapeutics on June 6, 2024.

Director Spike Loy acquired options to purchase 7,688 Class A Ordinary Shares in MoonLake Immunotherapeutics on June 6, 2024.

MoonLake Immunotherapeutics CEO, Jorge Santos da Silva, sold shares of the company's Class A ordinary stock between February 27 and February 29, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, executed multiple sales of Class A ordinary shares under a pre-arranged Rule 10b5-1 trading plan.